key: cord-0857417-x08fitwv
authors: Baldolli, Aurelie; Michon, Jocelyn; Appia, Fanny; Galimard, Caroline; Verdon, Renaud; Jacques Parienti, Jean
title: Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease : a case control study
date: 2021-06-23
journal: Vaccine
DOI: 10.1016/j.vaccine.2021.06.054
sha: 7cffb33b359b498ac80b4acb4cc25df7ae2b46fe
doc_id: 857417
cord_uid: x08fitwv

INTRODUCTION: Studies evaluating BNT162b2 mRNA Covid-19 vaccine safety excluded subjects with a previous history of COVID-19 infection. The aim of our study was to focus on the tolerance of this vaccine this population. METHODS: An anonymous self-reporting survey related to safety and tolerance of vaccine was completed by subjects 21 to 28 days after the first vaccine dose in two vaccination centers. RESULTS: Subjects with prior COVID-19 disease history (n=61) had higher systemic reactions than subjects without any previous history (n=1987) (45.9% vs 29.7%, p=0.01). Asthenia, headache and fever were significantly more frequent in COVID-19 + group than negative group (25.6% vs 15.2% p=0.045, 19.7% vs 9.3% p=0.01, 6.5% vs 0.9% p=0.003 respectively). Grade of severity was higher in COVID-19 + than in COVID-19 - group (p=0.03). CONCLUSION: Our study confirms a higher risk of side effects in patients with preexisting SARS-CoV-2 disease but with a good overall tolerance.

The objective of this study is to compare the tolerance of the first shot of BNT162b2 mRNA COVID-19 vaccine between subjects with and without history of previous SARS-CoV-2 infection.

An anonymous self-reporting survey related to safety and tolerance of BNT162b2 mRNA 

This survey was used to collect information regarding demographic characteristics (sex, age), characteristics and date of prior COVID-19 disease, post vaccine symptoms (severity and duration). Patients were considered to have a medical history of COVID-19 disease if they had a documented preexisting SARS-Cov-2 infection (serology or PCR). Local reaction was defined as local pain or local eruption on site of the vaccine injection. Systemic reaction was defined as all others symptoms than those included in the definition of local reaction such as fever, headache, myalgia, gastro intestinal symptoms, pulmonary symptoms, neurological symptoms, chills, general rash, arthralgia, asthenia, adenitis. Patients can develop local and/or systemic reaction.

No sample size computation was performed and we included all consecutive data available. We compared the side effects, the number of side effects, the sum of the side effect grades and the worst side effect grade among subjects with (case) and without (control) prior COVID-19 infection using Student t-test for independent samples in the overall cohort or Fischer test when appropriate. In addition, we matched 3 to 12 controls based on age and sex for each case. In the matched analysis, the comparison of the number of side effects, sum of the grades and mean of the worst grade the number of side effects, the sum of the side effect grades and the worst side effect grade among cases and control was performed by generalized linear model with exchangeable correlation structure, to take into account the correlation within each matched cluster. Continuous variables were expressed as means, and categorical variables were reported as percentages. The analyses were done with SAS V9.4 (SAS institute, Cary, NC) and a p-value<0.05 was used to denote statistical significance. This study was approved by the ethics committee of Caen Hospital (ID 2202) and was performed in accordance with the Declaration of Helsinki.

During the inclusion period, 2048 subjects completed the survey prospectively. Median age was 60 years (18-100) and 60.7% were female. 42.3% (n=867) of population had no side effect after the first dose while 46% (n=943) had a local reaction,30.1% (n=618) a systemic reaction among which 380 subjects had both local and systemic reaction. The most frequent systemic side effects were asthenia (15.5%), myalgia (12.7%) and headache (9.6%) ( Table 1) . Symptoms generally resolved within 3 days and only 192 subjects (9.3%) reported a side effect higher than grade 1. On the 1181 subjects with an adverse events, only one reported the side effect to the national pharmacovigilance system. Some patients reported COVID-like symptoms after de vaccine shot, but these where nonspecific and mimicked flue like illness. The time between illness (< or > 6 months) and vaccination did not affect the occurrence (76.2% for COVID-19 < 6 months group vs 73.2%

for COVID-19 > 6 months group, p=0.99) or severity of side effect (mean of grade 0.92 for COVID-19 < 6 months group vs 0.86 for COVID-19 > 6 months group, p=0.7).

COVID-19 + and COVID-19 -group were comparable for age and sex (Table 1) . Regarding all side effects, COVID-19 + group had significant higher rate of systemic reaction post vaccine than COVID-19 -group (45.9% vs 29.7%, p=0.01) while they had significant lower rate of absence of side effect than COVID-19 -group (26.2% vs 42.8%, p=0.01). Asthenia, headache and fever were significantly more frequent in COVID-19 + group than in COVID-19 -group (25.6% vs 15.2% p=0.045, 19.7% vs 9.3% p=0.01, 6.5% vs 0.9% p=0.003 respectively). The mean severity and duration of these 3 systemic symptoms were not different between the two groups (Table 1) . However, participants with a history of COVID-19 had higher peak side effect (p = 0.03) and sum of grade of side effects (1.75 vs 1.14, p=0.006) level than COVID-19 patients. Number of side effect was also higher in COVID-19 + group as compared to the COVID-19 -group (1.45 vs 0.96 p=0.0016).

As reported for the whole population, side effect were significantly more frequent in the COVID-19+ group than in the COVID-19 -matched group for age and sex (1.46 vs 1.04, p=0.02). Severity of side effect was also significantly higher in the COVID 19+ group (Table   2 ). We share new data on tolerance in patients with a previous history of COVID-19 infection. The local reaction was similar but we observed more frequent systemic side effects with a higher severity grade in patients with a previous COVID-19 infection. None of these side effects required hospitalization and they usually resolved within a few days. Krammer and co have found that a single dose of mRNA vaccine resulted in a higher frequency of side effects in COVID-19 seropositive patients compared to seronegative patients (89% vs 46% respectively) with higher difference than in our study (73.8% vs 57.2% respectively). health care workers, subjects with previous immunity (n=24) had an anti-spike IgG level more than 140 fold from peak pre-vaccine levels and a level significantly higher than those found in infection-naïve participants. Anti-spike antibody titres post vaccine in these infection-naïve individuals are similar to titres in individuals who have had a previous COVID-19 infection. [9] An investigation into the immunogenicity 21 days after one dose of BNT162b2 mRNA vaccine among 514 Israeli healthcare showed that immunogenicity was similar by ethnicity and sex, decreased with age. But participants with prior COVID-19 infection had antibody titres one magnitude order higher than naïve individuals regardless of the presence of detectable IgG antibodies pre-vaccination. [10] In addition a single BNT162b2 vaccine dose induces a significantly stronger T-cell responses to spike peptides and a significantly higher virus neutralization titers in individuals with previous virus exposure compared to infection-naive individuals. [11] .

In the original paper, incidence of local side effects were similar between the first and the second dose while the second dose induced more adverse systemic reactions.

[4] A recent study also report that systemic symptoms were higher after the second dose of BNT162b2 mRNA vaccine especially vomiting, diarrhea, fatigue, muscle and joint pain. [12] We hypothesize that the first dose of vaccine correspond to a second dose in subjects with prior COVID-19 infection with a higher humoral and T-cell response which may lead to a higher post vaccine reactogenicity. However further studies are needed to explore if reactogenicity post vaccine is related to the intensity of post vaccination humoral and cellular response.

Indeed, the main limit of our study is the small number of subjects with a history of previous SARS-CoV-2 infection and the absence of post vaccination serologyHowever groups were comparable for age and sex and the design of matched controls study improves the validity of our results.

Our study confirms a higher risk of short term side effects in patients with documented preexisting SARS-CoV-2 disease but with a good overall tolerance of BNT162b2 mRNA Covid-19 vaccine. These data are reassuring and should encourage confidence in the vaccination of this population. 

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: